Perhaps, because the CannaDX is specifically designed to test Cannabis and is the biggest revenue generator, institutions intending to invest in MYDX will basically be investing in CannaDX and the future value of its data collection. Of course, one must also consider currently the AquaDX and OrganaDX, both can save lives by "trusting and verifying". AquaDX is most effective globally with compromised water sourced to a population as opposed to an idividual concerned about the glass of water left sitting out on the table unattended. AquaDX by nature will always score big with crises involving the masses, it's not MYDX exploiting the situation just because the company has a feasible and cost-effective solution. OrganaDX is more versatile in that it can test for harmful pesticides on not only cannabis but also foods claiming to be organic and non-organic foods. These two current solutions for social problems may not be as exciting revenue wise but with proper institutional funding to support proper marketing platform, global sales would skyrocket but it's unfortunate if for the time being that institutions stay away specifically because of CannaDX. As long as progress report continues to be absent, it's looking like market cap could dip below $10M. However, I believe the company as it is will continue to sustain through CannaDX sales and everything else the company is planning will continue to fall into place as it should.
